pipeline-prospector-insert
X

Find Clinical Drug Pipeline Developments & Deals for MRTX849

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Therapeutic Area filter
    Study Phase filter
      Country filter
        News Type filter
          Company filter
            refresh

            Companies By Therapeutic Area Full Screen

            Development Status Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MRTX849

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 15, 2020

            Details:

            The data to be presented will include preclinical findings on MRTX849, a novel and optimized KRAS G12C inhibitor.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): MRTX849

            Therapeutic Area: Oncology Product Name: Undisclosed

            Highest Development Status: Phase I/ Phase II Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Goldman Sachs & Co.

            Deal Size: $300.0 million Upfront Cash: Undisclosed

            Deal Type: IPO January 09, 2020

            Details:

            Mirati expects to use funds for general corporate purposes, including expenses related to clinical development of MRTX849 and sitravatinib, manufacturing scale-up, the preclinical development of KRAS G12D inhibitor